Celsius Holdings, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Celsius Holdings, Inc. on April 5, 2008. The report discloses material definitive agreements, unregistered sales of equity securities, and Regulation FD disclosures. The filing references events occurring in April, June, and November 2008, indicating a discrepancy between the report date and the event dates described in the text.
Key Financial Metrics and Transactions
- Debt Issuance: An 8% convertible note for $250,000 was issued on June 5, 2008.
- Equity Issuance: 11,184,016 shares of common stock were issued on June 10, 2008, to CD Financial, LLC.
- Debt Conversion: The equity issuance was in exchange for a $750,000 convertible note originally issued on April 4, 2008.
- Conversion Terms: The note was converted at 75% of the volume-weighted average price for the five trading days prior to June 10, 2008.
- Liquidity and Margins: The filing text does not provide clear values for revenue, profit, cash flow, margins, or overall liquidity positions.
Material Changes and Unusual Items
The primary material change is the conversion of a $750,000 debt obligation into a significant equity position (11.18 million shares). Additionally, the company announced the results of a fourth clinical study performed by the University of Oklahoma via a press release dated June 10, 2008.
Guidance, Outlook, and Risks
The filing does not contain specific financial guidance or management commentary regarding future outlook. The primary risk disclosed relates to the dilution of existing shareholders due to the issuance of over 11 million shares and the terms of the convertible notes. The filing incorporates by reference a press release regarding clinical study results, which may impact future product viability.
Investor Verification Checklist
- Verify the discrepancy between the filing date (April 5, 2008) and the event dates (June 2008) described in the text.
- Confirm the exact conversion price per share used for the 11,184,016 shares issued to CD Financial, LLC.
- Review the full text of the $250,000 convertible note (Exhibit 10.1) for specific conversion terms and maturity conditions.
- Obtain the press release regarding the University of Oklahoma clinical study to assess its impact on the company's product pipeline.
- Check subsequent filings to confirm if the $250,000 note was converted or repaid by the November 3, 2008 deadline.